We struggled for years to find the right messaging and voice to capture the profound vision for our disruptive medical device technology. The team at s2s PR excelled at crystallizing our value in fresh messaging, leading a rebuild of our website, and driving significant media awareness and investor validation of Opticyte and our Cell O2 Monitor as we launch our first observational study and prepare for our Series A. Working with s2s PR is one of the best decisions that Opticyte has made so far.
– Lori Arakaki, PhD CEO & Co-Founder Opticyte